Strategies, such as ICIs targeting CTLA-4, PD-1, and PD-L1, as well as CAR-T cell therapy, aim to reprogram the immune system to better recognize and eliminate tumor cells (24). This evidence concerns the gene CTLA4 and neoplasm.